Add-Shop E-Retail Limited Overview
Add-Shop E-Retail Limited is a Rajkot-based micro-cap that markets and distributes Ayurvedic healthcare products, nutraceuticals and food supplements, organic agricultural inputs (soil conditioners and organic fertilisers), animal feed supplements, herbal personal care, household and women's hygiene products under the "Add-Shop" brand. Distribution runs through a franchise and direct-selling network concentrated in rural and semi-urban India, with particular depth in Karnataka, Andhra Pradesh, Telangana and Gujarat. The company is closely intertwined with promoter-group entities: Dada Organics Ltd (founded 2004 by the promoters), Dadaji Lifescience Pvt Ltd and Scarnose International Ltd. Shareholders have approved related-party transactions with these entities of up to INR 250 crore per year, which exceeds the company's entire revenue. After explosive growth from FY2019 to FY2023, culminating in a INR 48.9 crore rights issue in 2022, margins collapsed from about 15% to about 2%. Receivable days stretched to 264, promoter holding fell to 27%, and the stock trades at roughly 0.14x book value.
Company's own description
The company's filings describe it in several overlapping ways that have shifted over time:
- FY2024-25 annual report (as summarised by Screener, citing p.48): The company is engaged in trading and distribution of organic fertilisers, Ayurvedic medicines and herbal cosmetic products.
Strategic update to BSE, 19 Dec 2023: The company presents itself as a prominent direct selling company based in Rajkot. Its range covers supplements, Ayurvedic medicine, nutraceuticals, food supplements, herbal cosmetics, personal care, household items and women's hygiene products. It stresses nutraceuticals aimed at post-COVID needs and urban lifestyles, including protein products.
MCA/IIFL company summary: The company markets and distributes Ayurvedic, food supplement, agricultural, animal feed supplement and personal care products. It distributes organic products to farmers for agricultural use and organic cattle-feed products for livestock.
Press releases (Oct 2022, Apr 2022): The company calls itself one of the country's first companies to promote organic farming and produce organic farm goods. It claims the promoter lobbied government on organic farming about 20 years earlier, which predates the company and refers to the promoter's personal work.
- Data-aggregator description (Upstox, derived from S&P/Refinitiv): The company manufactures through two fully automated manufacturing units.
Business model
| Element | Characterisation |
|---|---|
| Core activity | Branded distribution (largely asset-light) of FMCG-like health, agri-input and personal care SKUs |
| Channel | Franchise outlets ("Add-Shop" franchises, often branded locally as organic/Ayurveda/"savayava" shops), C&F (carrying & forwarding) agents, a direct-selling member network and an e-commerce ordering platform for members |
| Customer types | (1) Franchisees and distributors (B2B); (2) farmers buying organic agri-inputs and cattle-feed supplements; (3) retail consumers buying Ayurveda, nutraceutical and personal care products; (4) direct-selling "members/associates" |
| End-markets | Indian rural agri-inputs (organic/bio-fertiliser, soil conditioners); animal nutrition supplements; Ayurvedic OTC/wellness; nutraceuticals; herbal personal care; household consumables; Khadi apparel (per aggregator descriptions) |
| Revenue model | Almost entirely product sales (trading/distribution margin). No disclosed subscription, licensing or service revenue. Franchise fees, if any, are not separately disclosed |
| Value-chain position | Mid-stream brand-owner/distributor. Upstream sourcing is partly from promoter-group manufacturers (Dada Organics, Dadaji Lifescience); downstream sales go through franchisees and members rather than organised retail |
| Geography | 100% domestic India (no export revenue disclosed despite 2022 press-release mentions of export ambitions) |
Independent characterisation
Add-Shop is best understood as a promoter-led, network-marketing-style distributor of low-ticket rural consumables. Its economics depend on a few things: (a) recruitment and activation of franchisees and members; (b) credit extended to the channel; and (c) sourcing terms with related parties. The FY2021–FY2023 surge (revenue from INR 78 crore to about INR 197 crore, PAT about INR 19 crore per year) coincided with aggressive franchise additions, two bonus issues and a INR 48.9 crore rights issue. Since FY2024 the business shows the hallmarks of a channel that has been over-stuffed or under-collected:
-
Debtor days rose from 53 (FY2022) to 264 (FY2026).
-
The cash conversion cycle widened from 102 to 333 days.
-
Cumulative operating cash flow over FY2023–FY2025 was negative INR 74 crore.
-
Operating margins fell from about 15–16% to about 2%.
Revenue has stabilised at about INR 155 crore in FY2025 and FY2026 and grew 55% YoY in Q1 FY2027. However, profit per rupee of sales is now minimal. The governance structure (27% promoter holding, family directors, large related-party approvals, frequent auditor, CFO and CS turnover) is the central analytical issue.
Strategy
Stated strategy themes (from BSE business updates and press releases, 2021–2023)
No investor-day material or formal medium-term strategy document exists. The recurring themes in management communications are:
-
Distribution-network leverage. Management repeatedly says it will leverage its robust distribution network across the country for Ayurvedic and agriculture products, expanding by state through franchises and C&F agents.
-
Product-range expansion. It frames itself as continually developing new health-related products, such as the 7 Ayurveda launches (Dec 2021), the 14-product pipeline (Jan 2022), spices, tea and coffee (Jul 2022) and tulsi green tea (Feb 2023).
-
E-commerce enablement. A member platform lets franchisees and partners order from anywhere, with doorstep delivery.
-
Farmer-centric organic agriculture. "Poison-free farming" positioning, with farmer recognition programmes.
-
Post-COVID nutraceuticals and urban lifestyle products. Protein and nutraceutical products for urban consumers (Dec 2023 strategic update).
-
Capacity and export ambitions. The Q2 FY2023 press release mentions further strategic initiatives to add incremental capacity and to explore exports.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Related-party sourcing/sales framework renewal | Aug–Sep 2026 | Board (27 Aug 2026) and AGM (19 Sep 2026) approved material RPTs with Dada Organics, Dadaji Lifescience and Scarnose International (aggregate cap reported as up to INR 250 crore) | Approved |
| Debt reduction / working-capital release | FY2026 | Borrowings cut from about INR 38 crore to about INR 25 crore; CFO turned positive at INR 8 crore | Achieved FY2026 |
| Governance/compliance appointments | May 2025; Aug 2026 | Secretarial auditor and internal auditor appointments; secretarial auditor change approved | Ongoing |
| New franchise or product launches | — | None announced to BSE in the last 24 months in sources reviewed | — |
| ESG / sustainability commitments | — | None disclosed | — |
| Cost programmes with targets | — | None disclosed | — |
Medium-term targets / guidance
Management has not issued any quantitative guidance or medium-term financial targets.
Products & Services
The company does not publish a SKU-level catalogue in its exchange filings, and no pricing is disclosed. The catalogue below is compiled from BSE business updates, press releases and aggregator business descriptions. Launch years reflect the announcement date.
Ayurveda & nutraceuticals
| Product / line | Description | Target customer | Launch / latest | Source |
|---|---|---|---|---|
| GAUPIYUSH Capsule | Ayurvedic preventive health capsule positioned for all age groups | Retail consumers via franchise network | Promoted Jan 2022 | IssueWire release, 30 Jan 2022 |
| Aloe Vera Gel | Herbal gel, part of a 7-product Ayurveda launch | Retail consumers | Dec 2021 – Jan 2022 | BSE update 10 Jan 2022 |
| Immunity-oriented Ayurveda range (7 products) | Ayurveda-based products launched to expand range; names other than Aloe Vera Gel not disclosed | Retail | Dec 2021 | BSE update 27 Dec 2021 |
| Pipeline of 14 health & household products | Under development as of Jan 2022; launch status not disclosed | Retail | Announced Jan 2022 | BSE update 10 Jan 2022 |
| Nutraceuticals / specialised protein products | Post-COVID nutraceuticals aimed at urban lifestyles, including protein supplements | Urban consumers | Referenced Dec 2023 | BSE strategic update 19 Dec 2023 |
| Food supplements | General food-supplement category | Retail | Ongoing | MCA/IIFL summary |
Food & beverages
| Product / line | Description | Launch / latest | Source |
|---|---|---|---|
| Instant Green Tea with Tulsi Extract | Instant herbal tea | Feb 2023 | BSE update 6 Mar 2023 |
| Spices, tea & coffee range | Announced for national distribution under the Add-Shop brand, citing government food manufacturing licensing | Announced Jul 2022 | BSE update 25 Jul 2022 |
Agriculture inputs
| Product / line | Description | Target customer | Source |
|---|---|---|---|
| Organic fertilisers / soil conditioners | Core agri line; the FY2025 annual report names organic fertilisers as a principal traded category | Farmers (strong in Karnataka) | Screener citing FY2025 AR; MarketScreener |
| Organic farming products | "Poison-free farming" positioning linked to the promoter's mission | Farmers | Press releases 2022 |
Animal nutrition
| Product / line | Description | Target customer | Source |
|---|---|---|---|
| Organic cattle-feed / animal feed supplements | Supplements for livestock | Dairy farmers | MCA/IIFL summary; press release Oct 2022 |
Personal care, household & other
| Product / line | Description | Source |
|---|---|---|
| Herbal cosmetics / personal care | Herbal cosmetic and personal care range | FY2025 AR (via Screener); Dec 2023 update |
| Household items / home care | Everyday-use products | Dec 2023 update; MarketScreener |
| Women's hygiene products | Women's hygiene range (promoter-group Dada Organics also lists sanitary pads) | Dec 2023 update; IndiaMART |
| Khadi clothing | Distribution of Khadi apparel | Investing.com / MarketScreener descriptions |
| Books and others | Listed in aggregator description | Investing.com |
Platforms and services
| Platform | Description | Source |
|---|---|---|
| E-commerce member platform | Member/franchise ordering platform with doorstep delivery to franchisees; the basis for the 2020 rename | BSE updates Jan 2022, Aug 2022 |
| Franchise model | Add-Shop branded franchise outlets plus C&F agents; franchise fees not disclosed | BSE updates 2021–2023 |
Pricing model: Not publicly disclosed. Products are sold at MRP-based retail prices through franchisees, with trade margins to the channel.
Financial Narrative
Basis: standalone, INR crore. Primary source is Screener.in (C-MOTS data derived from audited annual results), cross-checked with Business Standard/Capital Market summaries and company press releases. Some Screener annual figures are rounded to whole crore; precise figures are used where a primary or press source provides them.
Income statement
Note on gross profit: Gross profit (revenue less cost of goods) is not separately available in the sources accessed. Screener's "Expenses" line combines COGS and operating costs. Gross profit is therefore not publicly disclosed in the sources reviewed.
Quarterly trajectory (13 quarters)
Source: Screener quarterly results; Business Standard for Q1FY25 and Q4FY25 cross-checks.
Data-quality flag: One aggregator (Univest blog, May 2026) reported Q4 FY2026 revenue of "Rs 18 crore" and PAT of "Rs 1.5 crore". This conflicts with filed-results-derived data (INR 56.99 crore revenue; INR 0.36 crore PAT) and appears to be an automated error.
Balance sheet
Items not publicly disclosed in the sources reviewed:
Cash and cash equivalents: Screener's net cash flow lines (+1, -1, +1, -1, 0) imply cash balances of no more than about INR 1–2 crore.
- Given the working-capital-heavy profile and the 2022 AGM approval to give security for loans of up to INR 50 crore, borrowings are likely predominantly short-term working-capital facilities.
Goodwill and intangibles: None disclosed; assumed nil (no acquisitions).
Derived metrics:
Net debt: approximately equal to gross borrowings given minimal cash. Approx. INR 25 crore at FY2026, down from about INR 38 crore at FY2025.
- Working capital (other assets less other liabilities and borrowings): about INR 33 (FY2022), 100 (FY2023), 104 (FY2024), 107 (FY2025) and 108 crore (FY2026). Nearly all equity, including the INR 48.9 crore rights proceeds, is tied up in working capital.
Interim data point: Total assets at 30 Sep 2025 were INR 129.57 crore, versus INR 155.46 crore at 31 Mar 2025 (ScanX summary of H1 FY2026 results).
Cash flow
Commentary on cash flow: The FY2023 financing inflow of INR 45 crore is the rights issue, and the same year's operating outflow of INR 45 crore shows the proceeds were consumed by working capital (receivables and inventory).
Large investing flows in FY2024 (+INR 9 crore), FY2025 (-INR 15 crore) and FY2026 (+INR 18 crore) are unusual for a company with negligible capex. They most likely represent loans and advances given and recovered, or deposits, possibly with related parties. The nature of these flows is not publicly disclosed in the sources reviewed and should be verified in the annual report cash flow notes.
The FY2026 reversal (positive CFO of INR 8 crore and investing inflow of INR 18 crore) funded about INR 27 crore of financing outflow, chiefly debt reduction from INR 38 crore to INR 25 crore.
Ratios
Ratio notes:
Current ratio: Not computable precisely without the current/non-current split. Using other assets ÷ (other liabilities + borrowings) as a proxy gives about 4.0x (FY2022), 3.3x (FY2023), 7.5x (FY2024), 3.5x (FY2025) and 3.8x (FY2026). The high ratio reflects receivable build-up rather than liquidity.
ROIC proxy: EBIT ÷ (equity + debt), approximate.
Interest coverage: FY2022–FY2023 values use rounded interest of INR 1 crore and are approximate.
Commentary on trends, inflections and drivers
Phase 1 — Hyper-growth (FY2019–FY2023). Revenue rose roughly ninefold from INR 22 crore (FY2019) to about INR 197 crore (FY2023). Operating margins expanded to 15–16%. Management attributed the growth to franchise additions across southern and eastern states, the e-commerce member platform and new Ayurveda/immunity products during COVID. Debtor days, however, jumped from 53 to 167 in FY2023 alone. Profit growth was recognised in the income statement but was not converting to cash (CFO of -INR 45 crore in FY2023).
Phase 2 — Margin collapse (FY2024). Revenue held at INR 203 crore but OPM fell to 3.7%. Q4 FY2024 recorded a INR 9.6 crore operating loss (OPM -16.4%) and a INR 6.99 crore net loss, with an effective tax rate of 48% for the year. The Q4 loss is consistent with a year-end write-down, provisioning or margin give-back to the channel. No explanation was available in the sources accessed. This inflection coincided with two statutory auditor resignations (Aug 2023, Feb 2024) and wholesale board changes.
Phase 3 — Contraction and stagnation (FY2025–FY2026). FY2025 revenue fell 23.6% to INR 155 crore. Debt rose to INR 38 crore to fund a further INR 10 crore operating cash outflow, and debtor days hit 229. In FY2026 revenue was flat, OPM halved to 2.1%, and PAT fell 68% to INR 1.05 crore. Cash flow improved: CFO was +INR 8 crore and debt was cut by about INR 13 crore, possibly through recovery of advances (investing inflow of INR 18 crore).
Phase 4 — Q1 FY2027 volume rebound without margin. Revenue of INR 45.64 crore (+55% YoY) is the second-highest quarter since Q4 FY2024. OPM stayed at 1.9% and PAT at INR 0.27 crore. TTM revenue is about INR 171 crore and TTM PAT about INR 1.12 crore. The business is regaining volume but has not restored pricing power or channel margins.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Related Entity Details
| Related entity | Relationship | Business | Listed? |
|---|---|---|---|
Dada Organics Ltd (formerly Dada Organics Pvt Ltd) | Founded 2004 by Dineshbhai and Jayshree Pandya; Dev Pandya a director since 29 Aug 2017 | Manufactures and markets animal feed, Ayurveda, agricultural and herbal cosmetic/personal care products (incl. sanitary pads per IndiaMART listing) | — |
Dadaji Lifescience Pvt Ltd | Dev Pandya a director | Not publicly disclosed; RPT counterparty since at least FY2023 | No (private) |
Scarnose International Ltd | Dev Pandya and Jigar Pandya appointed directors 26 Mar 2024 (Dev exited 29 May 2024) | Cotton bales/yarn trading, readymade garments | Yes, BSE 543537 |
Dadaji Home Mart | Promoters' venture launched c. Jan 2022 | Retail of Ayurvedic/household products | — |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue (INR Cr) | 203.06 | 155.13 | 154.65 |
Operating profit before D&A (INR Cr) | 7.57 | 6.28 | 3.29 |
Pre-tax income (INR Cr) | 6.06 | 4.52 | 1.51 |
Operating margin (%) | 3.73 | 4.05 | 2.13 |
YoY revenue growth (%) | 1.6 | -23.6 | -0.3 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 159.65 | 197 | 203.06 | 155.13 | 154.65 |
Total expenses excl. D&A and interest (INR Cr) | 131 | 168 | 195.49 | 148.85 | 151.36 |
Operating profit / EBITDA (INR Cr) | 25 | 29 | 7.57 | 6.28 | 3.29 |
Other income (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Interest expense (INR Cr) | 1 | 1 | 1.03 | 1.21 | 1.20 |
Depreciation (INR Cr) | 0.4 | 0.6 | 0.50 | 0.55 | 0.58 |
Pre-tax income (INR Cr) | 23 | 27 | 6.06 | 4.52 | 1.51 |
Tax rate (%) | 19 | 30 | 48 | 27 | 30 |
Net income (INR Cr) | 19.09 | 19.2 | 3.16 | 3.32 | 1.05 |
EPS basic (INR) | 4.96 | 6.77 | 1.12 | 1.17 | 0.37 |
EPS diluted (INR) | 4.96 | 6.77 | 1.12 | 1.17 | 0.37 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA / operating margin (%) | 16 | 15 | 3.73 | 4.05 | 2.13 |
Pre-tax margin (%) | 14.4 | 13.7 | 3.0 | 2.9 | 1.0 |
Net margin (%) | 12.0 | 9.7 | 1.6 | 2.1 | 0.7 |
Revenue YoY growth (%) | 103.2 | 23.4 | 3.1 | -23.6 | -0.3 |
Net income YoY growth (%) | 146.6 | 0.6 | -83.5 | 5.1 | -68.4 |
CAGR by Period
| Period | CAGR |
|---|---|
FY2021 (INR 78 crore) → FY2026 (INR 154.65 crore), 5-year | approx. 14.7% (Screener 5-yr: 15%) |
FY2023 → FY2026, 3-year | approx. -7.6% (Screener: -8%) |
FY2022 → FY2026, 4-year | approx. -0.8% |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 47.32 | 40.37 | 56.99 | 58.38 | 40.36 | 31.20 | 33.83 | 49.73 | 29.41 | 33.40 | 34.85 | 56.99 | 45.64 |
Operating profit (INR Cr) | 7.41 | 3.51 | 4.42 | -9.60 | 2.09 | 1.62 | 1.67 | 0.90 | 0.77 | 0.75 | 0.80 | 0.97 | 0.86 |
OPM (%) | 15.66 | 8.69 | 7.76 | -16.44 | 5.18 | 5.19 | 4.94 | 1.81 | 2.62 | 2.25 | 2.30 | 1.70 | 1.88 |
Net profit (INR Cr) | 5.27 | 2.35 | 2.52 | -6.99 | 1.15 | 0.88 | 0.92 | 0.36 | 0.21 | 0.23 | 0.26 | 0.36 | 0.27 |
EPS (INR) | 1.86 | 0.83 | 0.89 | -2.47 | 0.41 | 0.31 | 0.32 | 0.13 | 0.07 | 0.08 | 0.09 | 0.13 | 0.10 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 51 | 151 | 126 | 155 | 152 |
Fixed assets, net (INR Cr) | 7 | 6 | 6 | 5 | 6 |
Other assets: receivables, inventory, cash, loans (INR Cr) | 44 | 144 | 120 | 150 | 146 |
Total borrowings (INR Cr) | 3 | 1 | 13 | 38 | 25 |
Other liabilities incl. payables (INR Cr) | 8 | 43 | 3 | 5 | 13 |
Equity share capital (INR Cr) | 19 | 28 | 28 | 28 | 28 |
Reserves (INR Cr) | 20 | 79 | 82 | 85 | 86 |
Shareholders' equity (INR Cr) | 39 | 107 | 110 | 113 | 114 |
Book value per share (INR) | 20.3 | 37.8 | 38.9 | 39.9 | 40.2 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 9 | -45 | -19 | -10 | 8 |
Investing cash flow (INR Cr) | -3 | -1 | 9 | -15 | 18 |
Financing cash flow (INR Cr) | -5 | 45 | 11 | 24 | -27 |
Net cash flow (INR Cr) | 1 | -1 | 1 | -1 | 0 |
Free cash flow (INR Cr) | 6 | -45 | -19 | -10 | 7 |
Capex, approx. (INR Cr) | 3 | 0 | 0 | 0 | 1 |
CFO / operating profit (%) | 45 | -134 | -209 | -131 | 242 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 64.7 | 26.3 | 2.9 | 3.0 | 0.9 |
ROA on average assets (%) | 39.8 | 19.0 | 2.3 | 2.4 | 0.7 |
ROCE (%), Screener | 69 | 38 | 6 | 4 | 2 |
ROIC, pre-tax proxy (%) | 58 | 26 | 6 | 4 | 2 |
Debt / equity (x) | 0.08 | 0.01 | 0.12 | 0.34 | 0.22 |
Net debt / EBITDA (x) | 0.1 | 0.0 | 1.7 | 6.0 | 7.6 |
Interest coverage, EBIT / interest (x) | 24.6 | 28.4 | 6.9 | 4.7 | 2.3 |
Asset turnover (x) | 3.25 | 1.95 | 1.46 | 1.09 | 1.01 |
Debtor days | 53 | 167 | 155 | 229 | 264 |
Inventory days | 59 | 68 | 54 | 100 | 102 |
Payable days | 10 | 86 | 4 | 8 | 33 |
Cash conversion cycle (days) | 102 | 148 | 206 | 320 | 333 |
Working capital days | 81 | 159 | 176 | 207 | 284 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
India (INR Cr) | 203.06 | 155.13 | 154.65 |
Outside India (INR Cr) | 0 | 0 | 0 |
State Details
| State | Disclosed expansion activity | Date(s) |
|---|---|---|
Karnataka | 26 franchises + 4 C&F (Jul 2022); most of 25 franchises (Aug 2023); farmer award programmes in Bengaluru | 2022–2023 |
Andhra Pradesh | 21 franchises | May 2022 |
Telangana | 14 franchises | May 2022 |
Tamil Nadu | 10 franchises | Feb 2023 |
West Bengal | 10 franchises | Feb 2023 |
Bihar | 7 franchises | Feb 2023 |
Maharashtra, Uttar Pradesh | Franchises opened (part of 8 across 3 states) | Nov–Dec 2021 |
Gujarat | Home state (Rajkot HQ) | Ongoing |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Latest close | INR 5.76 (8 Oct 2026) | MarketsMojo |
52-week high / low | INR 10.00 / 5.26 | Screener (Sep 2026) |
All-time low (reported) | INR 6.30 on 24 Aug 2026, subsequently breached | MarketsMojo |
1-year return | -42% (Screener); -40.9% (ScanX) | — |
3-year price CAGR | -46% per year | Screener |
5-year price CAGR | -38% per year (Screener); cumulative 5Y -91% (ScanX) | — |
IPO price (2018) | INR 26; bonus-adjusted about INR 8.74 (after 3:4 and 7:10 bonuses) | Derived |
Rights price (2022) | INR 54; current price about 89% lower | Derived |
Beta | -0.77 (Simply Wall St) | — |
Valuation Multiples
| Multiple | Add-Shop | Basis |
|---|---|---|
P/E (TTM) | About 14.8x | TTM EPS INR 0.40 (Screener) |
P/B | About 0.14x | Book value INR 40.2 |
EV/Sales | About 0.24x | EV ≈ INR 16.3 crore market cap + INR 25 crore debt − minimal cash ≈ INR 41 crore; TTM sales INR 171 crore |
EV/EBITDA | About 12–13x | TTM EBITDA about INR 3.4 crore |
Dividend yield | 0% | No dividends ever paid |
Operating Metrics (count) and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Shareholders (count) | 22,774 | 46,889 | 40,118 | 35,022 | 31,376 |
Promoter holding (%) | 58.07 | 36.03 | 27.20 | 27.20 | 27.20 |
Book value per share (INR) | 20.3 | 37.8 | 38.9 | 39.9 | 40.2 |
EPS (INR) | 4.96 | 6.77 | 1.12 | 1.17 | 0.37 |
Capital Markets
| Item | Detail |
|---|---|
Dividend history & policy | No dividend declared since listing (0% payout every year, FY2017–FY2026). Screener flags "reporting repeated profits, not paying out dividend." No formal dividend policy disclosed |
Corporate actions | Bonus 3:4 (Jul 2020); bonus 7:10 (Jan 2022); rights at INR 54 (Aug–Sep 2022). equity capital has stayed at INR 28.31 crore since FY2023 |
Credit ratings (Moody's/S&P/Fitch) | None. No domestic rating (CRISIL/ICRA/CARE) identified in sources reviewed |
Debt maturity profile | Not publicly disclosed. Borrowings of about INR 25 crore (FY2026) are presumed short-term working-capital lines |
Analyst consensus | No coverage |
Analyst Conclusions
Guidance and consensus
Management provides no guidance, and no analyst consensus exists. Run-rate indicators:
-
TTM revenue about INR 171 crore (+19% TTM).
-
TTM PAT about INR 1.12 crore (-53% TTM).
-
Q1 FY2027 revenue INR 45.64 crore at 1.9% OPM.
Annualising Q1 FY2027 implies FY2027 revenue of about INR 170–190 crore. Unless OPM recovers, PAT would remain in the INR 1–2 crore range. This is an analyst extrapolation, not guidance.
Bull case
-
Asset backing with release potential. Book value of INR 40.2/share vs. a price of about INR 5.8. If receivables (264 days) normalise toward FY2022's 53 days, INR 40–50 crore of cash could be released, about three times the market cap. FY2026 already showed CFO of +INR 8 crore and debt cut by INR 13 crore.
-
Volume re-acceleration. Q1 FY2027 revenue rose 55% YoY. Operating leverage on a largely fixed overhead base could restore mid-single-digit margins. Each 1 percentage point of OPM on about INR 180 crore of revenue adds about INR 1.8 crore of EBITDA, roughly doubling current earnings.
-
Proven historic earnings power. The company earned INR 19 crore PAT in each of FY2022 and FY2023 on a similar asset base. Even a partial recovery would put the stock on a very low multiple.
Bear case
-
Earnings quality and related parties. RPT caps of up to INR 250 crore with promoter entities exceed total revenue. Opaque investing flows (±INR 9–18 crore per year) and 264 debtor days leave outsiders unable to verify the economic substance of sales or receivables.
-
Governance signals. Two auditor resignations within six months, three CFOs and three company secretaries since 2023, a promoter stake down to 27% and a combined Chair/MD role all point to elevated governance risk that typically keeps such stocks at deep discounts to book indefinitely.
-
Structural margin erosion. OPM has fallen for four straight years (16% to 2.1%), and the Q1 FY2027 revenue rebound came at 1.9% OPM. This suggests volume is being bought through channel margins or credit, not earned through brand strength.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters | Expected timing |
|---|---|---|
| Q2 FY2027 results | Whether 55% growth persists and whether OPM rises above 3% | By mid-Nov 2026 |
| H1 FY2027 balance sheet (Sep 2026) | Receivable and inventory trend; borrowings | With Q2 results |
| Half-yearly RPT disclosure | Actual transaction values with Dada Organics, Dadaji Lifescience, Scarnose | Nov–Dec 2026 and May 2027 |
| Appointment of a new Company Secretary | LODR compliance continuity | Overdue since Apr 2026 |
| FY2026 annual report notes | Auditor opinion and any emphasis of matter; loans and advances to related parties; receivable ageing and expected credit loss provisioning; contingent liabilities | Already filed (27 Aug 2026); requires review |
| Promoter shareholding changes / pledges | Alignment signal | Quarterly shareholding filings |
| Any resumption of business updates (franchise or product launches) | Signal of commercial re-engagement | Ad hoc |
Analyst verdict
Add-Shop E-Retail is a case study in how a fast-growing rural distribution story can turn into a capital trap. Between FY2021 and FY2023 the company quadrupled revenue to about INR 197 crore, reported roughly INR 19 crore of annual profit, issued two bonus rounds and raised INR 48.9 crore from public shareholders at INR 54 per share. Three years later the same business earns about INR 1 crore a year on more than INR 150 crore of sales. About INR 108 crore of shareholder capital sits in working capital, receivables take 264 days to collect, and the share price of about INR 5.8 is below even the bonus-adjusted 2018 IPO price.
The bull thesis is arithmetic: a price-to-book of 0.14x, a debt load of only 0.22x equity, a FY2026 cash-flow turnaround and a 55% revenue rebound in Q1 FY2027. If receivables are genuine and collectible, the equity is worth several times the market price.
That "if" is the entire investment question. Related-party transaction frameworks exceed annual revenue. Investing cash flows swing by up to INR 18 crore a year with no disclosed explanation. Two statutory auditors resigned within six months, and finance and compliance leadership has turned over repeatedly. The promoter, who owns only about 25%, controls the board through family directors and an executive chair. None of these is proof of impropriety, but together they explain why the market refuses to credit the book value.
Verdict: High-risk, low-visibility micro-cap. Priorities for that review are receivable ageing, expected-credit-loss provisioning, related-party balances and the auditor's report. A re-rating requires two to three consecutive quarters of positive operating cash flow, falling debtor days and a stable, independent finance and audit function. Until then the discount to book is better read as a risk premium than a margin of safety.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background / prior roles | Age | Latest compensation |
|---|---|---|---|---|---|
Dineshbhai (Dineshkumar) Bhanushankar Pandya (DIN 06647303) | Promoter, Chairman & Managing Director | Director since 20 Aug 2013; MD since 31 May 2018 | Visually impaired first-generation social entrepreneur; about 20 years of work on "Poison Free Farming, Rich Farmer, Progressive Village"; co-founder of Dada Organics (2004); described as "leading industrialist of Gujarat" | 48–51 (sources conflict) | — |
Shraddha Dev Pandya | Executive Director (appointed Additional Executive Director 2023) | Since 2023 | — | — | — |
Maharshi Jigar Pandya | Executive Director (appointed Additional Executive Director 2023) | Since 2023 | Promoter family member (inferred) | — | — |
Jayshree (Jayshreeben) Dineshbhai Pandya | Non-Executive Director (earlier Executive Director) | Since 2017 | Co-founder of Dada Organics; co-launched Dadaji Home Mart | About 52 (Investing.com) | Received director remuneration in H2 FY2023 per RPT disclosure; amount illegible in source |
Rajen P. Vyas | Chief Financial Officer | Since 10 Jul 2024 | — | — | — |
“—” = not publicly disclosed.
Board of Directors — Maulik M. Chavda
| Name | Role | Appointed | Notes |
|---|---|---|---|
Maulik M. Chavda | Non-Executive Independent Director; committee member | 28 May 2024 | Appointed during the May 2024 reconstitution |
Dhrumil Rameshbhai Gokani | Additional Non-Executive Independent Director | Nov 2023 | — |
Vivek Dadhania | Independent Director | — | Listed on MarketsMojo board list |
Kinjal Khunt | Independent Director | — | Listed on MarketsMojo board list |
Jitendra Pradipbhai Parmar | Independent Director | — | Listed on Investing.com (age 33) |
Manish Shrichand Bachani | Independent Director | — | Listed on Investing.com (age 33) |
Governance Overview
| Dimension | Assessment |
|---|---|
Chair/CEO separation | Not separated: Dineshbhai Pandya is Chairman and MD |
Family representation | 4 of about 8 directors are from the promoter family |
Independence | About 50% on paper; Simply Wall St notes an average board tenure of about 1.5 years, so the board is effectively newly constituted |
Turnover | Very high: at least 6 independent director exits (2023–2024), 3 CFO changes (Aug 2023, Jul 2024), 3 CS changes (Sep 2023 appointment, Apr 2024 and Apr 2026 resignations), 2 statutory auditor resignations (Aug 2023, Feb 2024) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
8 Aug 2023 | Statutory auditor resignation accepted | Firm name not captured in sources accessed |
19 Aug 2023 | Dev Dineshbhai Pandya resigns as Director & CFO | Later joined the Scarnose International board (Mar 2024) |
19 Aug 2023 | Jigar Dineshkumar Pandya and Deviben Dineshbhai Pandya resign as directors | Promoter family members exit the board |
19–21 Aug 2023 | Independent directors Yagnik Mundadiya and Rushabh Vora resign | — |
1 Sep 2023 | New Company Secretary appointed | Per FY2023 annual report |
6 Nov 2023 | Independent director Rajeshkumar Rasiklal resigns citing personal reasons; Dhrumil Gokani and another independent director appointed | Filing also notes a director who is son-in-law of the MD (promoter group) |
13 Feb 2024 | Statutory auditor (FRN 120457W, Rajkot) resigns, citing preoccupation; new auditor (FRN 125924W) appointed for FY2023-24 | Second auditor exit in six months |
8 Apr 2024 | CS Dhaval Sureshkumar Raychura resigns | — |
28–31 May 2024 | Independent director Jaikishan Vasdev Wadhwani (DIN 10383327) resigns; new independent directors including Maulik M. Chavda appointed; committees reconstituted | — |
10 Jul 2024 | CFO Pradipkumar Harjibhai Lathiya resigns; Rajen P. Vyas appointed CFO | — |
27 May 2025 | Jay Pandya & Associates appointed secretarial auditor; internal auditor appointed for FY2025-26 | — |
7 Apr 2026 | CS Vinita Sunil Thadani resigns, citing external career opportunities | — |
27 Aug 2026 | Board approves change of secretarial auditor | — |
Governance Detail
| Category | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
Promoters (%) | 62.99 | 58.07 | 36.03 | 27.20 | 27.20 | 27.20 |
Public (%) | 37.01 | 41.93 | 63.98 | 72.80 | 72.81 | 72.81 |
Shareholders (count) | 705 | 22,774 | 46,889 | 40,118 | 35,022 | 31,376 |
Major Shareholders
| Holder | Category | Stake (%) | Source |
|---|---|---|---|
Dineshbhai Bhanushankar Pandya | Promoter | 25.13 (MarketsMojo) / 25.4 (Simply Wall St) | Aggregators |
Other promoter-group members | Promoter | About 2.07 (balance of the 27.20%) | Derived |
JR Seamless Private Limited | Public (corporate) | 2.46 | MarketsMojo |
Institutional investors (FII/DII/MF) | — | Nil / not disclosed (no institutional holders identified) | Screener pattern shows only promoter/public |
Holders 4–10 | Retail / individuals | Not publicly disclosed in sources accessed | — |
Competitive Landscape
Key Competitors
| Competitor | Category overlap | Type | Approx. scale (INR Cr; latest FY) | Relative positioning vs. Add-Shop |
|---|---|---|---|---|
Patanjali Ayurved / Patanjali Foods | Ayurveda, FMCG, food | Large private / listed | Patanjali Foods about 31,000–34,000 (FY2025, approx.) | Dominant mass-market Ayurveda brand with national retail distribution |
Dabur India | Ayurveda OTC, personal care, food | Listed (NSE/BSE) | About 12,500 consolidated (FY2025, approx.) | Category leader; strong brands and distribution |
Himalaya Wellness | Herbal personal care, OTC | Private | — | Strong pharmacy-led herbal brand |
Baidyanath | Classical Ayurveda | Private | — | Traditional Ayurveda pharmacy brand |
Amway India | Direct selling: nutrition, personal care, agri (limited) | Private (subsidiary of a US parent) | — | Largest direct-selling peer; premium nutrition |
Vestige Marketing | Direct selling: wellness, agri ("Agri 82"), personal care | Private | — | Closest model peer (direct selling of wellness and agri products, rural reach) |
Modicare | Direct selling: wellness, personal care | Private | — | Direct-selling peer |
Godrej Agrovet | Animal feed, agri inputs | Listed | About 9,000–10,000 (FY2025, approx.) | Scale leader in compound feed |
Coromandel International | Fertilisers incl. organic/bio-inputs | Listed | About 24,000 (FY2025, approx.) | Scale leader in agri inputs |
Best Agrolife / regional bio-input makers | Agri inputs | Listed / private | — | Regional competition in bio-inputs |
Dada Organics Ltd | Animal feed, Ayurveda, agri, cosmetics | Promoter-group entity | — | Both supplier and potential competitor; overlapping portfolio |
“—” = not publicly disclosed.
Competitive Advantages & Vulnerabilities
| Advantages | Vulnerabilities |
|---|---|
Rural franchise network in Karnataka/AP/Telangana with farmer-level relationships (126 farmers recognised in a single 2022 programme) | Sub-scale: revenue under 1.5% of Dabur's |
Bundled offering across agri, animal feed and wellness serves the same rural household | No brand pull outside its network; minimal advertising capacity |
Promoter's social-entrepreneur narrative and decades of organic-farming advocacy | Dependence on related-party suppliers creates conflicts and margin opacity |
Asset-light model (fixed assets of about INR 6 crore) | Working capital is the real asset base: 264 debtor days signals weak channel bargaining power |
| — | Direct-selling model is subject to the Consumer Protection (Direct Selling) Rules, 2021 |
Peer Comparison FY2026
| Metric | Add-Shop E-Retail (FY2026) | Dabur India (FY2025, approx.) | Godrej Agrovet (FY2025, approx.) | Patanjali Foods (FY2025, approx.) |
|---|---|---|---|---|
Revenue (INR Cr) | 154.65 | 12,500 | 9,400 | 33,000 |
Revenue growth (%) | -0.3 | 1 | 0 | 6 |
EBITDA margin (%) | 2.1 | 19 | 8 | 6 |
Net margin (%) | 0.7 | 14 | 4 | 4 |
R&D intensity (% revenue) | — | about 1 (approx.) | — | — |
“—” = not publicly disclosed.
Recent Developments
The company's disclosure cadence has slowed sharply since 2023, with no business updates and only statutory filings. All identified events are listed below.



